Natixis Blueprint Medicines Corp Transaction History
Natixis
- $17.6 Billion
- Q3 2024
A detailed history of Natixis transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Natixis holds 554 shares of BPMC stock, worth $50,757. This represents 0.0% of its overall portfolio holdings.
Number of Shares
554
Previous 583
4.97%
Holding current value
$50,757
Previous $62,000
17.74%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding BPMC
# of Institutions
351Shares Held
60.3MCall Options Held
2.25MPut Options Held
1.18M-
Vanguard Group Inc Valley Forge, PA6.68MShares$612 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.65MShares$609 Million0.02% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD5.39MShares$494 Million0.06% of portfolio
-
Wellington Management Group LLP Boston, MA3.96MShares$363 Million0.07% of portfolio
-
State Street Corp Boston, MA2.77MShares$253 Million0.01% of portfolio
About Blueprint Medicines Corp
- Ticker BPMC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,719,600
- Market Cap $5.47B
- Description
- Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...